Technology Transfer Partnerships
Technology transfer driver in the Asia-Pacific region
IVI has partnered with six manufacturers from five Asian countries for the technology transfer of new cholera and typhoid vaccines that range from a major industrial Korean conglomerate (SK Chemicals) to a government-affiliated vaccine manufacturer in Vietnam (VaBiotech).
|Tech transfer partner||Status|
|VaBiotech, Vietnam||Bivalent killed whole-cell oral cholera vaccine
Partnered with VaBiotech on modifying the vaccine and tech-transferred quality control assays and reagents; vaccine currently licensed and used in Vietnam as mORC-VAX.
|Shantha Biotechnics, India||Bivalent killed whole-cell oral cholera vaccine
Partnered with Shantha on clinical development, licensure in India, and WHO prequalification; Shanchol™ WHO-prequalified in 2011 and currently used in the WHO stockpile.
|EuBiologics, South Korea||Bivalent killed whole-cell oral cholera vaccine
Currently working with EuBiologics on late-stage clinical development; Euvichol expected to be WHO- prequalified in 2016.
|SK Chemicals, South Korea||Typhoid conjugate vaccine (Vi -DT)
Currently working with SK Chemicals on clinical development; vaccine expected to be WHO-prequalified by 2020.
|PT BioFarma, Indonesia||Typhoid conjugate vaccine (Vi-DT)
Currently working with BioFarma on clinical development; vaccine expected to be WHO-prequalified by 2019.
|Incepta Vaccine Ltd., Bangladesh||Bivalent killed whole-cell oral cholera vaccine
Typhoid conjugate vaccine (Vi- DT)
Currently working with Incepta on clinical development and licensure of the two vaccines for the domestic market.